Full coverageLilly to appeal as U.K. declines to endorse use of new Alzheimer’s drugs
By Dulan Lokuwithana
Top News
NICE reaffirms negative stance on Alzheimer's therapies Kisunla, Leqembi
Breakthrough Alzheimer's drugs too pricey to be offered on NHS
By James Gallagher
Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug
By Sriparna Roy and Devika Syamnath
Final draft guidance finds benefits of 2 Alzheimer’s treatments remain too small to justify the additional cost to the NHS
All coverage
Why Nice was right to say no – for now – to new Alzheimer’s drugs
By Paul Atkinson and Sally Sheard
Why people can't access dementia 'wonder' drugs
By Genevieve Bates
NICE concludes decision for two Alzheimer’s treatments
By Catherine Eckford
U.K. decision blocks a pair of Alzheimer’s drugs from access through its national health service
By Andrew Joseph
Breakthrough dementia drugs rejected AGAIN for use on NHS – as experts blast it ‘can’t keep up with scien...
By Sam Blanchard
Not Over Yet: Eisai And Lilly To Appeal England’s ‘Flawed’ Refusal To Fund Leqembi And Kisunla
By Neena Brizmohun
Alzheimer’s drugs ruled ‘too pricey’ for NHS use
By Hanna Geissler
NHS patients denied first drugs that treat Alzheimer’s
By Eleanor Hayward
Why Nice was right to say no – for now – to new Alzheimer’s drugs
By Sally Sheard and Paul Atkinson
Lilly to appeal after UK agency opposes reimbursement for Alzheimer's drug
By Sriparna Roy and Devika Syamnath